Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.21 extracted from

  • Shinagawa, K.; Ploplis, V.A.; Castellino, F.J.
    A severe deficiency of coagulation factor VIIa results in attenuation of the asthmatic response in mice (2009), Am. J. Physiol. Lung Cell Mol. Physiol., 296, L763-L770.
    View publication on PubMedView publication on EuropePMC

Application

Application Comment Organism
medicine the efficacy of recombinant factor VIIa for the reversal of anticoagulation in patients with warfarin-associated intracranial hemorrhage is described in several case reports, case series, and retrospective cohort studies. Its use may be considered for as a viable alternative treatment to standard treatment with fresh-frozen plasma. Patients should be screened for increased risk of thrombosis before administration of the drug Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-
Mus musculus
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining

Synonyms

Synonyms Comment Organism
factor VIIa
-
Mus musculus
factor VIIa
-
Homo sapiens

General Information

General Information Comment Organism
malfunction eosinophil counts in the bronchoalveolar lavage fluid of wild-type mice increases after ovalbumin challenge, a response that is diminished in comparably challenged low-expressing coagulation factor VII (FVIItTA/tTA) mice. Levels of T helper type 2 cytokines, IL-4, IL-5, and IL-13, and eosinophil-attracting chemokines, eotaxin and RANTES, are also lower in the ovalbumin-challenged low expression factor VIIa mice. Eosinophils purified from low-FVII mice undergo apoptosis at a faster rate compared with wild-type eosinophils, and eosinophil migration in response to eotaxin is reduced in eosinophils obtained from low expressing factor VIIa mice. Airway hyperresponsiveness and mucous layer thickness are reduced in ovalbumin-treated low expressing factor VIIa mice Mus musculus